Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board
SAN DIEGO, September 13, 2017
Zander Therapeutics, Inc., a subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB) announced the appointment of Robin Beat Gasser, DVM, Ph.D. as a Senior Veterinarian Advisor to the Company.
Dr. Gasser is among the world's most recognized parasite biologists and is Professor of Parasitology and Director of Research for the University of Melbourne's Veterinary School. Dr. Gasser was just named the Redmond Barry Distinguished Professor at the University of Melbourne. His research extends across both veterinary and medical parasitology, and is distinguished by his contributions to understanding parasitic diseases, as well as his focus not only on fundamental biology, but also practical applications to improving disease control in the field. His contributions have been recognized internationally through numerous awards, prizes and honors including an Alexander von Humboldt Professorial Research Prize, Bayer Prize for Research Excellence and a Fulbright Senior Scholarship.
Download full press release here
From Princeton University: An interdisciplinary team of researchers, including those from Princeton University, sequenced a region of chromosome 6 in dogs and found multiple sections of canine DNA that were associated with differences in social behavior. In many cases, unique genetic insertions called transposons on the Williams-Beuren syndrome critical region (WBSCR) were strongly associated with the tendency to seek out humans for physical contact, assistance and information.
In contrast, in humans, it is the deletion of genes from the counterpart of this region on the human genome, rather than insertions, that causes Williams-Beuren syndrome, a congenital disorder characterized by hyper-social traits such as exceptional gregariousness.
Zander Therapeutics Inc. Announces Brian Devine, Former Chairman of PETCO, to Helm its Business Advisory Board
Brian Devine, retired Chairman of PETCO, a leading pet specialty retailer, has agreed to serve as Chairman of the Business Advisory Board for Zander Therapeutics, Inc., a veterinary life sciences company and subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB). "Mr. Devine's vast expertise in the animal health market, as well as his legacy of support for pet health, are an ideal match for our company," says David Koos, PhD, Chairman and CEO of Zander. "He understands the business networks we navigate, and we are honored to have our company associated with such an accomplished individual in the pet care industry."
Zander Therapeutics :: Specializing in cutting edge therapies for animals
Founded in 2015 as a biotechnology company focused on veterinary medicine, specifically small molecule treatments for veterinary cancers, autoimmune diseases such as arthritis and other immunotherapies for specialty niche treatments.
Copyright Zander Therapeutics, Inc. 2018